Group 1 - The company has confirmed that its recombinant respiratory syncytial virus (RSV) vaccine utilizes a novel adjuvant rather than a traditional aluminum adjuvant [2] - The announcement was made in response to an inquiry from investors on an interactive platform [2] - The vaccine is developed using CHO cells, indicating a modern approach to vaccine production [2]